Evidence map›Paper›PMID 37495531›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Recurrent Stroke with Rapid Development of Intracranial Artery Stenosis and Subsequent Successful Mechanical Thrombectomy in Essential Thrombocythemia.

Yuji Kato, Shohei Iijima, Shinya Kohyama, Tomoya Maeda, Tsugumi Sato, Shinichi Takahashi, Satoshi Suda

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yuji KatoDepartment of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Japan.
Shohei IijimaDepartment of Endovascular Neurosurgery, Saitama Medical University International Medical Center, Japan.
Shinya KohyamaDepartment of Endovascular Neurosurgery, Saitama Medical University International Medical Center, Japan.
Tomoya MaedaDepartment of Hemato-Oncology, Saitama Medical University International Medical Center, Japan.
Tsugumi SatoDepartment of Pathology, Saitama Medical University International Medical Center, Japan.
Shinichi TakahashiDepartment of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Japan.
Satoshi SudaDepartment of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Japan.
Saitama Medical University · JPSaitama International Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Essential thrombocythemia is a myeloproliferative neoplasm. Ischemic stroke is frequently the first manifestation of essential thrombocythemia. We herein report a patient with JAK2V617 mutation-positive essential thrombocythemia who developed recurrent ischemic stroke with rapid development of intracranial artery stenosis and subsequently underwent successful mechanical thrombectomy. The high JAK2V617F allele burden in our patient (58.4%) may have affected the patient's condition. We discuss similar reports in the literature and the possible pathophysiologic mechanism of large artery involvement in these patients.

Indexed as

Ischemic StrokeThrombocythemia, EssentialArteriesCerebral InfarctionConstriction, PathologicHumansJanus Kinase 2MutationThrombectomyJanus Kinase 2early/prefibrotic primary myelofibrosisessential thrombocythemiahistopathologyJAK2V617 allele burden

Identifiers

PMID37495531
PMCPMC11009006
OpenAlexW4385254846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.